A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The National Institute on Drug Abuse Clinical Trials Network launched the Prescription Opioid Addiction Treatment Study (POATS) in response to rising rates of prescription opioid dependence and gaps in understanding the optimal course of treatment for this population. POATS employed a multi-site, two-phase adaptive, sequential treatment design to approximate clinical practice. The study took place at 10 community treatment programs around the United States. Participants included men and women age ≥18 who met Diagnostic and Statistical Manual, 4th Edition criteria for dependence upon prescription opioids, with physiologic features; those with a prominent history of heroin use (according to pre-specified criteria) were excluded. All participants received buprenorphine/naloxone (bup/nx). Phase 1 consisted of 4 weeks of bup/nx treatment, including a 14-day dose taper, with 8 weeks of follow-up. Phase 1 participants were monitored for treatment response during these 12 weeks. Those who relapsed to opioid use, as defined by pre-specified criteria, were invited to enter Phase 2; Phase 2 consisted of 12 weeks of bup/nx stabilization treatment, followed by a 4-week taper and 8 weeks of post-treatment follow-up. Participants were randomized at the beginning of Phase 1 to receive bup/nx, paired with either Standard Medical Management (SMM) or Enhanced Medical Management (EMM; defined as SMM plus individual drug counseling). Eligible participants entering Phase 2 were re-randomized to either EMM or SMM. POATS was developed to determine what benefit, if any, EMM offers over SMM in short-term and longer-term treatment paradigm. This paper describes the rationale and design of the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“This type of research design is an example of a practical clinical trial [19], which has been applied elsewhere in psychiatry [20] and general medicine [21].”
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351 · cited 2×
“[27] study referenced above, the investigators found lower medication adherence and lower treatment retention with SMM than with EMM, but little between-group difference in the amount of reduction of illicit opioid use.”
BackgroundResultSample Size Calculations for Studies with Correlated Observations
Liu, G., & Liang, K.-Y. (1997) · Biometrics · doi:10.2307/2533554 · Cited by 306 · cited 1×
“Based on a test statistic proposed by Liu and Liang [39], employing GEE to account for correlation among measurements of patients from the same site, we determined that a total of 324 subjects would be needed for Phase 2.”
MethodPersistent pain is associated with substance use after detoxification: a prospective cohort analysis
Larson, M. J., Paasche‐Orlow, M., Cheng, D. M., Lloyd‐Travaglini, C., Saitz, R., & Samet, J. H. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01759.x · Cited by 204 · cited 1×
“Both of these would be good prognostic characteristics, although the greater frequency of pain problems in prescription opioid users [12–14] could counterbalance this, since co-occurring pain has generally been a poor prognostic indicator in patients with substance use disorders [15].”
BackgroundClinical efficacy of buprenorphine: comparisons to methadone and placebo
LING, W. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00059-0 · Cited by 121
Self-citationSullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.008 · Cited by 110
Cited by
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
“1) determined whether patients would require extended buprenorphine-naloxone treatment (phase 2); details of the study methods, including interventions, are described elsewhere.(21)”
Self-citationInitiation into prescription opioid misuse amongst young injection drug users
Lankenau, S. E., Teti, M., Silva, K., Bloom, J. J., Harocopos, A., & Treese, M. (2012) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2011.05.014 · Cited by 440
“Initiation into prescription opioid misuse is an important public health concern since opioids are increasingly associated with drug dependence (SAMSHA, 2008a; Weiss et al., 2010) and fatal overdose (Paulozzi & Xi, 2008; SAMSHA, 2010b).”
Garland, E. L., Manusov, E. G., Froeliger, B., Kelly, A., Williams, J. M., & Howard, M. O. (2014) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0035798 · Cited by 431
“Single item measures of craving have been shown to distinguish high- from low-risk opioid using chronic pain patients and predict opioid misuse (Wasan et al., 2009; Weiss et al., 2010).”
BackgroundDiscontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
“Notably, high relapse rates were observed in young adults (Woody et al., 2008) as well as primary prescription opioid abusers (Sigmon et al., 2013;Weiss et al., 2010), populations often considered to be have better prognoses (Dreifuss et al., 2013; Moore et al., 2007; Sigmon, 2006).”
McHugh, R. K., Fitzmaurice, G. M., Carroll, K. M., Griffin, M. L., Hill, K. P., Wasan, A. D., & Weiss, R. D. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.10.002 · Cited by 133
“…previous 30 days, history of heroin injecting, or history of opioid dependence based on heroin use alone), a significant pain condition for which ongoing opioid therapy was indicated, or any medical or psychiatric condition contraindicated for study participation were excluded (Weiss et al., 2010).”
BackgroundSelf-citationBlanco, C., Iza, M., Schwartz, R. P., Rafful, C., Wang, S., & Olfson, M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.013 · Cited by 61
Benzodiazepine Misuse among Adults Receiving Psychiatric Treatment
McHugh, R. K., Peckham, A. D., Björgvinsson, T., Korte, F. M., & Beard, C. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.020 · Cited by 25
Metadata
- Authors
- Weiss, R. D., Potter, J. S., Provost, S. E., Huang, Z., Jacobs, P., Hasson, A., Lindblad, R., Connery, H. S., Prather, K., & Ling, W.
- Venue
- Contemporary Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 31
- Issue
- 2
- Pages
- 189-199
- ISSN
- 1551-7144 (ISSN-L)
- OpenAlex
- W2059724256
- Cited by
- 76
- References
- 7
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.